FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Revolution pushes home its pan-KRAS advantage
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
Venture cash funds first human trials
Private company trial initiations stand out in the latest week’s disclosures.
Christmas holiday round-up
As the biotech markets turned bullish the sector’s ups and downs continued.
Akeso builds on earlier success with bispecifics
Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.
ASCO Plenary – what Astellas does Keymed might do better
Keymed’s AstraZeneca-partnered anti-Claudin18.2 ADC looks better than Astellas’s zolbetuximab – albeit on an extremely unreliable metric.
